Diasorin SpAWBO:DIAS +2.47%74 ROC (Joel Greenblatt) % is 29.43% as of Dec. 2025, which is 58% below its 10-year median of 69.29. GuruFocus rates WBO:DIAS with a GF Score™ of 74/100 and a GF Value™ of €90.06 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Diasorin SpA ranks better than 86.26% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Diasorin SpA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 29.43%.
The historical rank and industry rank for Diasorin SpA's ROC (Joel Greenblatt) % or its related term are showing as below:
WBO:DIAS'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 40.92 Med: 69.29 Max: 95.07
Current: 47.63
During the past 13 years, Diasorin SpA's highest ROC (Joel Greenblatt) % was 95.07%. The lowest was 40.92%. And the median was 69.29%.
WBO:DIAS's ROC (Joel Greenblatt) % is ranked better than 86.26% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.02
vs WBO:DIAS: 47.63
Diasorin SpA's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -17.10% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Diasorin SpA ROC (Joel Greenblatt) % Related Terms
Diasorin SpA ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:DIAS vs TMO, DHR, IDXX: ROC (Joel Greenblatt) % Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 29.43% mean?
Diasorin SpA (WBO:DIAS) has a ROC (Joel Greenblatt) % of 29.43% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Diasorin SpA and its competitors. This is 58% below median its historical median of 69.29. Over the past decade, Diasorin SpA's ROC (Joel Greenblatt) % has ranged from 40.92 to 95.07. According to the industry distribution chart, Diasorin SpA ranks #29 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 13.7%.
Is Diasorin SpA's ROC (Joel Greenblatt) % too high?
Diasorin SpA's current ROC (Joel Greenblatt) % of 29.43% is 58% below median its 10-year median of 69.29. Over the past 10 years, this metric has ranged from a low of 40.92 to a high of 95.07. Based on the distribution chart, Diasorin SpA ranks #29 out of 211 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Diasorin SpA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's ROC (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #29 out of 211 companies for ROC (Joel Greenblatt) %. This places Diasorin SpA in the top 14% of its industry — outperforming the majority of peers. Historically, Diasorin SpA's own ROC (Joel Greenblatt) % has ranged from 40.92 to 95.07 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Diasorin SpA and its competitors. Diasorin SpA's current ROC (Joel Greenblatt) % is 29.43%, which is 58% below median its own 10-year median of 69.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (WBO:DIAS) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.06, compared to a current price of €69.68 — trading 22.6% below its estimated fair value. The current ROC (Joel Greenblatt) % is 29.43%, which is 58% below median its 10-year median of 69.29. Diasorin SpA's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Diasorin SpA (WBO:DIAS), the current ROC (Joel Greenblatt) % is 29.43% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (WBO:DIAS) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €69.68 is trading 22.6% below its estimated GF Value™ of €90.06.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for WBO:DIAS:
ROC (Joel Greenblatt) %: 29.43% (58% below median its 10-year median of 69.29)
GF Value™: €90.06 vs. price of €69.68 (22.6% below fair value)
No single metric tells the full story. See the WBO:DIAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
74GF Score
Get the complete analysis for WBO:DIAS
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:DIAS has been successfully added to your 
